NasdaqGM - Nasdaq Real Time Price USD

Coherus BioSciences, Inc. (CHRS)

Compare

1.4700

-0.0400

(-2.65%)

At close: January 10 at 4:00:01 PM EST

1.5000

+0.03

+(2.04%)

After hours: January 10 at 7:01:30 PM EST

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

- Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer - REDWOOD CITY, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that an abstract highlighting final clinical and biomarker data from its Phase 2 clinical trial evaluating casdozokitug (casdozo), a selective and potent IL-27-antagonistic antibody, in combination with atezolizumab (atezo) and bevaciz

GlobeNewswire 24 days ago

CHRS
-2.65%
Sector Update: Health Care Stocks Decline Premarket Tuesday

Health care stocks were declining premarket Tuesday, with The Health Care Select Sector SPDR Fund (X

PREMIUM
MT Newswires last month

CHRS
-2.65%
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.

- Coherus to focus exclusively on innovative immuno-oncology programs that include LOQTORZI®, an FDA approved, next-generation programmed cell death protein 1 (PD-1) inhibitor - - Proceeds to fund development of key combination programs with LOQTORZI, including casdozokitug, a first-in-class, clinical-stage interleukin-27 (IL-27) antagonist, and CHS-114, a highly selective chemokine receptor 8 (CCR8) antibody - - Post-closing proceeds to repay the entirety of the company’s $230 million convertib

GlobeNewswire last month

CHRS
-2.65%
Coherus, sharpening immuno-oncology focus, sells another biosimilar for over $500M

The company reached a deal to divest its third biosimilar this year, selling a copycat version of Amgen’s Neulasta for up to $558 million.

BioPharma Dive last month

CHRS
-2.65%
Q3 2024 Coherus BioSciences Inc Earnings Call

Q3 2024 Coherus BioSciences Inc Earnings Call

Thomson Reuters StreetEvents 2 months ago

CHRS
-2.65%
Coherus BioSciences Inc (CHRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...

Coherus BioSciences Inc (CHRS) reports significant revenue growth and market share gains, despite facing supply interruptions impacting future sales projections.

GuruFocus.com 2 months ago

CHRS
-2.65%
Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue Estimates

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 90% and 24.44%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

CHRS
-2.65%
Coherus BioSciences: Q3 Earnings Snapshot

REDWOOD CITY, Calif. AP) — Coherus BioSciences Inc. CHRS) on Wednesday reported a loss of $10.8 million in its third quarter.

Associated Press Finance 2 months ago

CHRS
-2.65%
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

– Net revenue of $70.8 million in Q3 2024 driven by 30% increase in UDENYCA® net revenue, quarter-over-quarter – – UDENYCA labeling and packaging production resuming at third-party contract manufacturing organization – – LOQTORZI® launch progressing to plan, revenues increase 50% quarter-over-quarter – – Innovative immuno-oncology pipeline advancing to proof-of-concept studies in combination with toripalimab – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif., Nov. 06, 202

GlobeNewswire 2 months ago

CHRS
-2.65%
Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024

REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its third quarter 2024 financial results will be released after market close on Wednesday, November 6, 2024. Starting at 5:00 p.m. ET on November 6, 2024, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the c

GlobeNewswire 2 months ago

CHRS
-2.65%
Coherus BioSciences Inc (CHRS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Coherus BioSciences Inc (CHRS) reports a 10% increase in total revenue and significant progress in its oncology portfolio, despite ongoing challenges.

GuruFocus.com 3 months ago

CHRS
-2.65%
Coherus BioSciences, Inc. (CHRS): Worst 52-Week Low Stock to Buy Now

We recently compiled a list of the 15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers. In this article, we are going to take a look at where Coherus BioSciences, Inc. (NASDAQ:CHRS) stands against the other Worst 52-Week Low Stocks. The U.S. Federal Reserve conducting a 50 basis point interest rate cut was the […]

Insider Monkey 3 months ago

CHRS
-2.65%
^GSPC
Short Interest Surges to 21.83% as Coherus BioSciences, Inc. (CHRS) Faces Revenue Challenges

We recently published a list of 15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers. In this article, we are going to take a look at where Coherus BioSciences, Inc. (NASDAQ:CHRS) stands against the other worst 52-week low stocks to buy now according to short sellers. The U.S. Federal Reserve conducting a […]

Insider Monkey 3 months ago

CHRS
-2.65%
^GSPC
Institutional owners may take dramatic actions as Coherus BioSciences, Inc.'s (NASDAQ:CHRS) recent 12% drop adds to one-year losses

Key Insights Institutions' substantial holdings in Coherus BioSciences implies that they have significant influence...

Simply Wall St. 3 months ago

CHRS
-2.65%
Coherus BioSciences Second Quarter 2024 Earnings: Beats Expectations

Coherus BioSciences ( NASDAQ:CHRS ) Second Quarter 2024 Results Key Financial Results Revenue: US$65.0m (up 11% from 2Q...

Simply Wall St. 4 months ago

CHRS
-2.65%
Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 33.33% and 13.85%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 5 months ago

CHRS
-2.65%
Coherus BioSciences: Q2 Earnings Snapshot

REDWOOD CITY, Calif. AP) — Coherus BioSciences Inc. CHRS) on Thursday reported a loss of $12.9 million in its second quarter.

Associated Press Finance 5 months ago

CHRS
-2.65%
Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update

– Net revenue of $65.0 million in Q2 2024 – – CHS-114 Phase 1 Study Recruitment Continues into Expansion Cohorts in Head and Neck Cancer in Combination with LOQTORZI – – Bryan McMichael Appointed as Chief Financial Officer – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today reported financial results for the quarter ended June 30, 2024 and recent business highlights: RECENT BUSINESS

GlobeNewswire 5 months ago

CHRS
-2.65%
Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024

REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its second quarter 2024 financial results will be released after market close on Thursday, August 8, 2024. Starting at 5:00 p.m. EDT on August 8, 2024, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conc

GlobeNewswire 5 months ago

CHRS
-2.65%
PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar

European drug regulators voted for a third time not to renew the approval of Translarna. Elsewhere, Sanofi invested in a brain disease biotech and Esperion sold royalties to help pay off a loan.

BioPharma Dive 6 months ago

ESPR

PTCT

SNY

Performance Overview

Return	CHRS	S&P 500
YTD	-2.00%	-1.35%
1-Year	-50.67%	+22.51%
3-Year	-89.98%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Coherus BioSciences, Inc. (CHRS)

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

Sector Update: Health Care Stocks Decline Premarket Tuesday

Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.

Coherus, sharpening immuno-oncology focus, sells another biosimilar for over $500M

Q3 2024 Coherus BioSciences Inc Earnings Call

Coherus BioSciences Inc (CHRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...

Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue Estimates

Coherus BioSciences: Q3 Earnings Snapshot

Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024

Coherus BioSciences Inc (CHRS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Coherus BioSciences, Inc. (CHRS): Worst 52-Week Low Stock to Buy Now

Short Interest Surges to 21.83% as Coherus BioSciences, Inc. (CHRS) Faces Revenue Challenges

Institutional owners may take dramatic actions as Coherus BioSciences, Inc.'s (NASDAQ:CHRS) recent 12% drop adds to one-year losses

Coherus BioSciences Second Quarter 2024 Earnings: Beats Expectations

Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates

Coherus BioSciences: Q2 Earnings Snapshot

Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024

PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar

Performance Overview